The Biggest Drug Competition in 2021 (Hint: It Isn't COVID Vaccines)

Brian Orelli, PhD, The Motley Fool
·4-min read

In this video from Motley Fool Live, recorded on Jan. 4, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com contributor Brian Orelli discuss the upcoming four-way competition for patients with eczema. Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) have captured a large share of the moderate-to-severe patients with their injected drug Dupixent. Corinne Cardina: Any other big indications that you're going to watch this year beyond Biogen?